

**Response to Kuvan® in subjects with PKU from a single centre in
Norway**

ME026

EudraCT No: 2009-012978-12

Clinical Trial Results

Sponsor's Protocol Code Number	ME026
Title	A Phase IV, prospective, open-label, uncontrolled, single-centre cohort trial conducted in Norway to assess the responsiveness of subjects with phenylketonuria (PKU) to treatment with Kuvan® 20 mg/kg/day for 7 days
Trial Phase	IV
EudraCT Number	2009-012978-12
Sponsor*	Merck Serono, an affiliate of E. Merck AB
Primary Objectives	The primary objective is to identify subjects with PKU responsive to Kuvan® ($\geq 30\%$ reduction from baseline in blood PHE level) in a single centre in Norway using the 24-hour BH4 loading test.
Overall Trial Status	Cancelled (no patients have been enrolled)

Merck KGaA

These results are supplied for information purposes only.